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Introduction: Metformin is a biguanide used to treat diabetes mellitus (DM). Metformin-associated 
lactic acidosis (MALA) carries a high mortality and can occur in patients with renal failure from drug 
bioaccumulation. Reversible vision loss is a highly unusual, rarely reported complication of MALA. 
We present a case of a patient whose serum metformin concentration was unusually high and 
associated with vision loss. 
Case Report: A 60-year-old woman presented to an outside hospital emergency department 
with acute vision loss after being found at home confused, somnolent, and hypoglycemic, having 
last being seen normal two days prior. She reported vomiting and diarrhea during that time 
and a recently treated urinary tract infection. The visual loss resolved with continuous renal 
replacement therapy.
Conclusion: This novel case of a patient with type II DM prescribed metformin and insulin who 
developed reversible vision loss while suffering from MALA highlights the potential for vision loss in 
association with MALA. [Clin Pract Cases Emerg Med. XXXX;X(X):X–X.] 
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INTRODUCTION 
Metformin-associated lactic acidosis (MALA) is a 
potentially life-threatening adverse effect of metformin use 
with the incidence ranging from approximately 10-11 in 
100,000 persons per year.1,2 Historically, from 1960-2000, it 
carried a 50% mortality rate; however, the mortality rate has 
improved to approximately 25-30% since 2000.3,4 Reversible 
vision loss is a highly unusual complication of MALA and has 
very rarely been reported.5-9 
Metformin is a small drug (165 kilodalton) with an oral 
bioavailability of 50%. Since it is not metabolized by the liver, 
tubular secretion is the primary elimination route.10 The 
mechanism of action of metformin includes affecting the 
formation of adenosine triphosphate production by decreasing 
the efficiency of mitochondrial oxidative phosphorylation.11 
Another mechanism of metformin includes the inhibition of 
mitochondrial glycerophosphate dehydrogenase. When this is 
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affected, the balance of cytosolic nicotinamide adenine 
dinucleotide and hydrogen (NADH) is altered. There is then 
more NADH available, which decreases lactate to pyruvate 
conversion.12 Therefore, lactate can accrue, either as a result of 
increased metformin ingestion or decreased clearance.13 To 
maintain acid-base homeostasis, lactate is metabolized by 
gluconeogenesis or oxidation after converting to pyruvate, and 
the proton reacts with bicarbonate to form water and carbon 
dioxide.13 The kidney replenishes bicarbonate by reabsorption 
at the tubular level or net acid secretion.14,15 However, once 
these compensatory mechanisms are exhausted, bicarbonate is 
depleted, and lactate accumulates. Despite administering 
intravenous (IV) sodium bicarbonate to replace the depleted 
bicarbonate stores, the patient may require extracorporeal 
removal of these substances to aid in combating the effects of 
metformin by both removing metformin and correcting the 
acid-base disturbances.
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What do we already know about this clinical 
entity? 
Metformin Associated Lactic Acidosis (MALA) is a 
life-threatening adverse effect of metformin usage 
with a mortality rate of approximately 25-30%.
What makes this presentation of disease 
reportable?
This case presents a rare symptom of MALA, 
reportable vision loss.
What is the major learning point?  
In order for emergency physicians to expedite 
proper critical care, recognizing the common and 
uncommon signs of MALA is crucial.
How might this improve emergency medicine 
practice?  
By noticing the symptoms of metformin associated 
lactic acidosis, it will allow emergency physicians 
to provide best practice patient care. 
CASE REPORT
A 60-year-old woman with past medical history of 
diabetes mellitus prescribed insulin and metformin developed 
total vision loss. She was transported to the emergency 
department (ED) after being discovered at home confused, 
somnolent, and hypoglycemic, and last seen normal two days 
prior. The patient reported vomiting, diarrhea, and a recently 
treated urinary tract infection (UTI). She was never able to 
provide an exact history, but her sister reported to the ED staff 
that she had developed a UTI treated with an unknown 
antibiotic approximately one week prior to the current visit. 
The patient also reported to her sister diarrhea and weakness 
for one day prior to arrival to ED. Per emergency medical 
services (EMS), her initial blood glucose was 42 milligrams 
per deciliter (mg/dL) (reference range: 70-100 mg/dL) and 
improved after IV administration of 25 grams of glucose in a 
50-cubic centimeter prefilled syringe (50% dextrose). No 
suspicion of surreptitious ingestion of medications was 
described by either EMS or family. 
In the ED the patient’s vital signs were as follows: 
temperature 31.1°C (88°F); heart rate 58 beats per minute; 
respiratory rate 22 breaths per minute; blood pressure 90/43 
millimeters mercury; and oxygen saturation 100% on room 
air. On physical examination, she was awake but ill-appearing 
and confused, demonstrating neither any vision perception nor 
blink reflex. Notable laboratory results are listed in the table. 
Rewarming measures, IV fluids, and IV infusions of sodium 
bicarbonate, vasopressors (norepinephrine and vasopressin), 
folic acid, thiamine, 4-methylpyrazole, and empiric antibiotics 
(vancomycin and cefepime) were all administered. The patient 
received 4-methylpyrazole due to initial diagnostic uncertainty 
and significantly low bicarbonate concentration; it was 
discontinued when toxic alcohol ingestion was eliminated. 
The patient was moved to an intensive care unit (ICU) at a 
tertiary care referral center
In the ICU the patient received continuous renal 
replacement therapy due to anuria. Continuous renal 
replacement therapy was initiated instead of hemodialysis due 
to persistent hypotension despite multiple vasopressors. She 
also was treated with IV sodium bicarbonate given her 
profound and persistent acidemia. Her vision improved, and 
she was able to track movement and perform extraocular 
movements. Eventually she had total resolution of her visual 
deficits. However, she developed pulmonary edema requiring 
intubation and, despite some improvement in acidemia and 
kidney function (Figure), she required maximal vasopressor 
support including IV infusions of epinephrine, norepinephrine, 
vasopressin, angiotensin, methylene blue, and steroids.
Admission and subsequent daily serum metformin 
concentrations measured 57 micrograms per milliliter (µg/mL), 
42 µg/mL, and 13 µg/mL (therapeutic 1-2 µg/mL; MALA 
typically associated with more than 5 µg/mL). Serum liquid 
chromatography and mass spectroscopy toxicology screen did 
not include metformin concentrations and detected no other 
xenobiotics. Blood cultures, viral panels, chest radiograph, and 
chest, abdomen and pelvis computed tomography were 
unrevealing other than “minimal enterocolitis.” The patient 
unfortunately expired on hospital day three.
DISCUSSION
Recommended indications (and associated levels of 
evidence) for extracorporeal treatment for metformin poisoning 
include the following: lactate concentration greater than 20 
millimoles per liter on day one, pH less than or equal to 7.0 (day 
one), shock (day one), failure of standard supportive measures 
(day one), and decreased level of consciousness on day two.4 
Documented vision loss associated with MALA and 
reversible blindness is very rare and unique to this case is the 
highest recorded, concurrent metformin concentration (57 µg/
mL). Kreshak et al reported a metformin concentration of 28 
µg/mL in a patient with vision loss; the patient fully recovered 
after hemdialysis.5 Cigarran et al described a 54-year-old male 
patient with funduscopic examination findings revealing 
bilateral proliferative diabetic retinopathy with vitreous 
hemorrhage. This patient also had recovery of vision, but no 
serum concentration was available.6  
The proposed mechanism of MALA-induced vision loss 
is that function of the retinal cells is related to the potential 
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hydrogen (pH).5 Studies demonstrate in certain animal 
species such as fish, tiger, and salamanders that there is a 
pH-sensitive response to light by the retinal horizontal cells.5 
These cells are laterally interconnecting neurons located 
in the inner nuclear layer of the retina that help integrate 
input from multiple photoreceptor cells. Animal models 
demonstrate that this transmission is disrupted in acidosis 
with a serum pH less than 7.0. If extrapolated to humans, this 
could explain the reason for loss of vision in the associated 
severe acidosis.6 Sudden vision loss has also been reported 
previously with both diabetic and alcoholic ketoacidosis. The 
common denominator among these patients was both a severe 
metabolic acidosis and reversal of abnormal vision symptoms 
with correction of serum pH.7 This patient had improvement 
and then resolution of her vision loss as her pH rose above 
7.0. The patient’s serum metformin concentration of 57 µg/
mL (therapeutic range 1-2 µg/mL) is the highest reported 
concentration associated with MALA-induced vision loss.  
CONCLUSION
This is a novel case of a patient with type II diabetes 
mellitus prescribed metformin and insulin who developed 
MALA-induced, reversible vision loss with the highest 
measured, concurrent metformin concentration. Because 
MALA portends a high mortality, it is crucial for emergency 
physicians to recognize both the common and uncommon 
signs and symptoms to expedite proper critical care. 
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Table. Notable lab results for patient presenting with total vision loss.
Test name Result (reference range)
WBC 28,900 K/cmm (4.0-10.0 K/cmm)
Hgb 10.7 g/dL (11.5-14.5 g/dL),
Hct 36.6% (35.0-43.0%)
Platelet 261,000 (140-350 thou/cmm)
Glucose 216 mg/dL (70-100 mg/dL)
BUN 74 mg/dL (7-18 mg/dL)
Creatinine 9.38 mg/dL (0.40-1.00 mg/dL)
Na+ 135 mmol/L (136-145 mmol/L)
K+ 5.8 mmol/L (3.5-5.1 mmol/L)
Cl- 93 mmol/L (98-107 mmol/L)
HCO3- 4 mmol/L (21-32 mmol/L)
CPK 285 U/L (less than201 U/L)
Lipase 857 U/L (73-393 U/L)
Lactate 22.3 mmol/L (0.4-2.0 mmol/L)
Troponin I 0.06 ng/mL (0.00-0.05 ng/mL)
Pro-BNP 3912 pg/mL (0-125 pg/mL)
Prothrombin time 19.2 sec (12.0-14.6 sec)
Initial arterial blood gas on 
4 liters nasal cannula
pH <6.94 (7.35-7.45),  
CO2 <20 mm Hg (32-45 mm Hg), 
pO2 188 mm Hg (83-108 mm Hg)
Acetaminophen, 
salicylate, ethanol, and 
toxic alcohol panel
All negative
WBC, white blood cells; K, thousands; cmm, cubic millimeter; 
Hgb, hemoglobin; g, grams; dL, deciliter; Hct, hematocrit; thou, 
thousands; mg, milligrams; BUN, blood urea nitrogen; Cr, 
creatinine; Na+, sodium; mmol, millimoles per liter; K+, potassium; 
Cl-, chloride; HCO3-, bicarbonate; CPK, creatine phosphokinase; 
U, units; ng, nanograms; mL, milliliters; pg, picograms; sec, 
seconds; CO2, carbon dioxide; mm Hg, millimeters of mercury.
Figure. Laboratory findings of patient during hospital stay.
HD, hospital days; CCRT, continuous renal replacement therapy; 
HCO3, bicarbonate.
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